Internship Opportunity As Diabetes Educator at ADLD
Qualification: BSC or D Pharm
Share your CV at : [email protected]

• 11, Hill Road, Sector F 6/2 Islamabad
• Call us: 051 9208244

For more details and to know about our organization and work visit our official website www.adldpk.com

Imran Abbas is a Famous Pakistani actor and model. He is known for his leading roles in various famous television serials and Bollywood movies. He supports ADLD (Alliance For Diabetes And Liver Disease) and its component CDLD (Center For Diabetes And Liver Disease) in fighting diabetes and spreading awareness among people who are at risk. Become a member of ADLD to support our cause.

Activity at IESCO G7 Islamabad to spread the awareness about the modern epidemic, DIABETS. Purpose of the activity was to screen the people who are at risk of developing diabetes and educating the people to develop lifestyle to prevent this disease including healthy cooking. Of various slogans, one was "No Child Should Die of Diabetes"

Outline
Indications
Milan Criteria
Expanded Milan Criteria (UCSF)
Upto 7 Criteria
MELD Scoring and T staging
Criteria for down staging
LT versus LDT
Pre transplant Evaluation
Procedure
Follow up


Indications: The Milan Criteria
1996, Italy, 48 patients, Mazzafero et al

Single lesion less than 5 cm
Less than 3 lesions none exceeding 3cm
No extrahepatic involvement
No vascular invasion

overall and recurrence-free survivals were 85% and 92%
overall recurrence rate was 8% at 4 years’ follow-up

UCSF-Expanded Milan Criteria
2001

Solitary tumor < 6.5 cm,
or < 3 nodules with the largest lesion < 4.5 cm
and total tumor diameter < 8 cm




Schwartz, Liver Transplantation for Hepatocellular Carcinoma, Gastroenterology.  2004: 127 S268-276.
Vascular invasion

Mc Gill Protocol
Tumors exceeding Milan criteria
Receive 3 TACE treatments at 6 week intervals
Lipiodol,carboplatinum, gelfoam
If patients respond (AFP decreases or tumors shrink, then go on to LT, otherwise continue care)

Upto 7 criteria
HCC with 7 as the sum of the largest tumor (cm) and the number of tumors
Downstaging
LT versus LDT
LDT includes
TACE
RFA
PEI

The published observational studies to date suggest survival following OLT is at least as good as following resection in patients with adequate hepatic reserve.
Liver resection can leave residual liver which is of insufficient size to provide adequate function and as stated before, has the possibility of developing further lesions.
In patients with well-compensated cirrhosis (Child Pugh A) and HCC, the decision whether to resect or transplant remains controversial. However, in the current realm of organ shortage and long waiting times, the decision to resect in this group appears attractive.
If tumor recurrence were to recur than salvage transplantation can be performed.

 An observational series has shown primary OLT to have lower operative mortality, recurrence rates and survival rates
Requirements for listing
UNOS provides a set of specific requirements for listing patients with HCC:
(1)Rough evaluation of the number and size of tumors and to rule out extra-hepatic spread by ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) plus CT of the chest;
(2) Prelisting biopsy is not mandatory, however patients must have one of the following:
(a) a biopsy confirming HCC;
(b) a vascular blush corresponding to the area of suspected HCC;
(c) an α fetoprotein (AFP) > 200 mg/mL;
(d) an arteriogram confirming a tumor;
(e) a history of local ablative therapy(TACE, RFA, PEI);
(3) Patients with chronic liver disease and a rising AFP > 500 mg/dL can also be listed even in the absence of discrete tumor on imaging studies;
(4) The patient must not be a resection candidate;
(5) Reimaging by CT or MRI every 3 mo is required to ensure continued eligibility for OLT.
Bridging therapy
The “dropout” due to tumor progression whilst waiting for OLT is reported to be at least 20%
This problem has furthered the use of local-regional adjuvant therapy (LDT) whilst awaiting transplantation such as TACE, RFA, and PEI.


The ultimate aim of LDT is to provide complete tumor necrosis in an attempt to halt tumor progression.
Analyses of explant specimens subjected to RFA and TACE have shown complete tumor necrosis rates of 47%-66% and 16%-27%, respectively
A retrospective study looking at tumor necrosis in 61 patients did not find any particular modality of LDT to be superior.
Prognostic Factors
Conforming to the “Milan criteria”, in terms of tumor size and tumor burden, gives rise to 3-4-year recurrence free survival rates of up to 92%

Multivariate analysis has shown these to be the only independent variables predicting patient survival and tumor recurrence. Other biological factors such as tumor grading, microvascular invasion and microsatellites appear to play a role, but within the constraints of the size and number burden.

The histological grade of the tumor can be assessed by lesional biopsy and several authors have recommended this approach. Lesional biopsy does however carry the risk of tumor seeding which has been estimated at approximately 2%

Furthermore, significant histological heterogeneity has been described in large tumors, which limits the utility of needle biopsy
Live donor LT
Living donor liver transplantation (LDLT) has evolved over the past decade, mainly in response to the scarcity of donor livers. Deceased liver donation is particularly scarce in Asia, where organ donation rates are less than 5 donors per million population compared to 10-35 per million in Western countries.

LDLT, in particular right liver transplantation, has dramatically increased the number of potential donors. This can eliminate the problem of long waiting times and ‘dropout’ whilst waiting for an organ because of disease progression.
Furthermore, as there is no direct ‘competition’ from other potential transplant recipients the restrictive criteria on tumor burden can be relaxed somewhat.

Survival rates-same as OLT
Recurrence rates-higher

No consensus guidelines for indications
LDLT carries a risk to the donor during hepatectomy with morbidity and mortality rates of 14%-21% and 0.25%-1%, respectively

Using a scoring system including the measurement of “protein induced by vitamin K absence or antagonist-Ⅱ” (PIVKA-Ⅱ), a Japanese group have achieved a 5-year recurrence rate of only 4.9%. PIVKA-Ⅱ, also known as des-carboxyprothrombin, is an abnormal prothrombin protein found in the serum of patients with HCC and in patients with vitamin K deficiency or on warfarin therapy





Overall survival after olt

Post Transplant Surveillance
Imaging every 3-6 months for 2 years, then annually
AFP if initially elevated-then q3mo for 2 years then q6mo

Joint Diseases
Pre Rehab Assessment
Functional assessment (ie, transfer status, analysis of gait, activities of daily living);
Range of joint motion (ROM) (for all joints);
Muscle strength test (manual or by isokinetic equipment);
Postural assessment; and
Evaluation of respiratory function


Cold/Hot Applications
Cold/hot modalities are the most commonly used physical agents in arthritis treatment. It is well known that cold application is mostly used in acute stages whereas hot is used in chronic stages.

By using heat, analgesia is accomplished, muscle spasm relieved, and elasticity of periarticular structures obtained.
Heat can be used before exercise for maximum benefit. Thermotherapy may be applied as a superficial hot-pack, infrared radiation, paraffin, fluidotherapy, or hydrotherapy. Applications are recommended for 10–20 minutes once or twice a day. Caution is necessary in patients with sensorial deficits and impaired vascular circulation in hands and feet because of burn risk. 

Cold application is preferred in active joints where intra-articular heat increase is undesired. Cold-pack, ice, nitrogen spray, and cryotherapy are different methods of applying cold-therapy.

Levels of destructive enzymes such as collagenase, elastase, hyaluronidase, and protease are affected by the temperature of local joints.
With temperatures of 30° Celsius or lower, effects of these enzymes are negligibly small. Normal intra-articular temperature is 33° Celsius, whereas it may rise up to 36° Celsius in patients with inflammation.
Increasing intra-articular temperature is also related to an increase in collagenase activity and cartilage damage. Despite the inhibition of cell proliferation and metabolic activation within the synovial fluid at 41–42° Celsius, it cannot be used as a therapeutic method because of irreversible joint damage
Electrical Stimulation
Transcutaneous electrical nerve stimulation (TENS) therapy is the most commonly used method.

The highest frequency TENS is the most beneficial, with an analgesia that persists up to 18 hours.

Various studies have reported an increase in hand grip strength after daily application of 15 minutes of TENS and a decrease in pain after using TENS once a week for 3 weeks

Reduction of synovial fluid and inflammatory exudate following TENS application in acute arthritis and suggested that pain relief may be partially explained by this effect. 

Postoperative pain control by TENS therapy following knee joint arthroplasty reduces need for analgesic drugs and hospital stays.
It also has a high placebo effect.
It cannot be used in every painful joint simultaneously, which is a disadvantage in patients with polyarticular involvement. 
Rehabilitative treatment
Joint Protection Strategies
1.Rest and Splinting

Rest and splinting
The joints should be put into rest during the acute stage of the disease.
Bed rest relieves the pain in cases of extensive joint involvement.
It is critical, at this stage, to put the joints into rest at a functional position. Rest position should be as follows: shoulder joint in 45° abduction, both wrist joints in 20° to 30° dorsal flexion, fingers slightly in flexion, hips at 45° abduction without any flexion, knees totally extended, and feet in a neutral position.

Splints may be used to give desired position at rest and functional positioning to the involved active joints. Increased compliance can be gained by offering the patient splints made of soft materials
Orthosis and splinting are used for the following objectives
to diminish pain and inflammation,
to prevent development of deformities,
to prevent joint stress,
to support joints, and
to decrease joint stiffness.

Major factors determining patient compliance to the orthosis are size of the orthosis, the heat generated at the skin by the orthosis, hardness of the parts in contact with the skin, and whether it interferes with functions

Joint stress in the feet may be alleviated by medial arc supporting pad at the sole of the foot and by metatarsal pad. Viscoelastic soles may decrease shock loading occurring at proximal tibia during the gait, by up to 40%.
Compression Gloves
Patients using compression gloves have reported reduced joint swelling and increased well-being.
However, there is no positive evidence regarding improved grip strength or hand functions from using gloves.
Improvement may be provided by using compression gloves for hour intervals or only at night in patients with inflammation in their hands or fingers.
Gentle compression is beneficial because of the containment of joint swelling and subsequent decrease of pain.
Assistive Devices and Adaptive Equipment
Occupational therapy interventions such as assistive devices and adaptive equipment have beneficial effects on joint protection and energy conservation in arthritic patients.
Assistive devices are used in order to reduce functional deficits, to diminish pain, and to keep patients' independence and self-efficiency.
Loading over the hip joint may be reduced by 50% by holding a cane
Massage Therapy
Massage is a commonly used treatment tool that improves flexibility, improves general well being, and can help to diminish swelling of inflamed joints
Pain thresholds both at the massage site and at the knee and ankle decrease after applying oscillatory manual massage to the intervertebral paraspinal region.
Massage is found to be effective on depression, anxiety, mood, and pain.
This finding leads to the question of whether there are some changes in peripheral nociceptive perception and central information in RA. Also, massage decreases stress hormone levels.
Therapeutic Exercise
Muscle weakness in patients may occur because of immobilization or reduction in activities of daily living.
Maintenance of normal muscle strength is important not only for physical function but also for stabilization of the joints and prevention of traumatic injuries.
It may be proposed that exercise therapy has beneficial effects on increasing physical capacity rather than reducing the activity of the disease.

Prior to establishing an exercise program for patients with joint diseases, the following characteristics should be considered:
whether the involvement of the joints is local or systemic,
stage of the disease,
age of the patient,
and compliance of the patient with the therapy.
Duration and severity of the exercise are adjusted according to the patient. ROM exercises, stretching, strengthening, aerobic conditioning exercises, and routine daily activities may be used as components of exercise therapy.

There should be no straining exercises during the acute arthritis.
However, every joint should be moved in the ROM at least once per day in order to prevent contracture.
In the case of acutely inflamed joints, isometric exercises provide adequate muscle tone without exacerbation of clinical disease activity.
Moderate contractures should be held for 6 seconds and repeated 5–10 times each day.

It should be remembered that if isometric exercises are performed in a magnitude of more than 40% of maximum voluntary contraction, they may lead to impairment in blood circulation and fatigue after the exercise.
If the disease activity is low, then isotonic exercises should be performed by using very low weights.
Low-intensity isokinetic knee exercises (by 50% of the maximum voluntary contraction) were reported to be safe and effective in patients

If pain persists more than 2 hours or too much fatigue, loss of strength, or increase in joint swelling occurs after an exercise program, then it should be revised.
Also, walking does not lead to intra-articular pressure increase in healthy subjects but does so in a knee with inflammation and effusion.
Thus, patients with active arthritis should particularly avoid activities such as climbing stairs or weight lifting.
Producing excessive stress over the tendons during the stretching exercises should be avoided.
In sudden stretches, tendons or joint capsules may be damaged.

Finally, in chronic stage with inactive arthritis, conditioning exercises such as swimming, walking, and cycling with adequate resting periods are recommended. They increase muscle endurance and aerobic capacity and improve functions of the patient in general, and they also make the patient feel better.

Patient Education
In patients with joint diseases, sociopsychological factors affecting the disease process such as poor social relations, disturbance of communication with the environment, and unhappiness and depression at work are commonly encountered

Multidisciplinary education with the participation of rheumatologists, orthopedicians, physiotherapists, psychologists, and social workers for patients with arthritis is preferable

In such programs, there is information about benefits and adverse effects of drug therapy, importance of physiotherapy, use of orthosis, psychological coping methods, self-relaxation, and various diets. In addition, patients are taught how to perform the scheduled exercises and how to protect the joints during routine daily life.

Step 1:Identifying Patients Who Need to Lose Weight  

Measure height and weight and calculate BMI at annual visits or more frequently.
 
Use the current cutpoints for overweight (BMI >25.0-29.9 kg/m2) and obesity (BMI ≥30 kg/m2) to identify adults who may be at elevated risk of CVD and the current cutpoints for obesity (BMI ≥30) to identify adults who may be at elevated risk of mortality from all causes
 



Advise overweight and obese adults that the greater the BMI, the greater the risk of CVD, type 2 diabetes, and all-cause mortality.
 
Measure waist circumference at annual visits or more frequently in overweight and obese adults.

Advise adults that the greater the waist circumference, the greater the risk of CVD, type 2 diabetes, and all-cause mortality.  

Need to lose weight
YES – BMI >30 or BMI 25<30 with additional risk factor(s): Weight loss treatment is indicated for 1) obese individuals and 2) overweight individuals with 1 or more indicators of increased CVD risk (e.g., diabetes, prediabetes, hypertension, dyslipidemia, elevated waist circumference) or other obesity related comorbidities  


NO – BMI <25 or BMI 25<30 without additional risk.
Normal weight patients (BMI 18.5<25) should be advised to avoid weight gain.
Patients who are overweight (BMI 25<30), and who do not have indicators of increased CVD risk (e.g., diabetes, prediabetes, hypertension, dyslipidemia, elevated waist circumference) or other obesity-related comorbidities should be advised to avoid additional weight gain  

Step 2:Matching Treatment Benefits With Risk Profiles  

Counsel overweight and obese adults with CV risk factors (high BP, hyperlipidemia and hyperglycemia), that lifestyle changes that produce even modest, sustained weight loss of 3%-5% produce clinically meaningful health benefits, and greater weight losses produces greater benefits.



Sustained weight loss of 3%-5% is likely to result in clinically meaningful reductions in triglycerides, blood glucose, HbA1C, and the risk of developing type 2 diabetes;
Greater amounts of weight loss will reduce BP, improve LDL–C and HDL–C, and reduce the need for medications to control BP, blood glucose and lipids as well as further reduce triglycerides and blood glucose.
 



At a 3 kg weight loss, a weighted mean reduction in triglycerides of at least 15 mg/dL is observed.
At 5 kg to 8 kg weight loss, low-density lipoprotein cholesterol (LDL–C) reductions of approximately 5 mg/dL and increases in high-density lipoprotein cholesterol (HDL–C) 2 to 3 mg/dL are achieved.
With <3 kg weight loss, more modest and more variable improvements in triglycerides, HDL– C and LDL–C are observed



At a 5% weight loss, a weighted mean reduction in systolic and diastolic BP of approximately 3 and 2 mm Hg respectively, is observed.
• At <5% weight loss, there are more modest and more variable reductions in BP.

Step 3: Determining Recommended goals for weight loss
A realistic and meaningful weight loss goal is an important first step. Although sustained weight loss of as little as 3% to 5% of body weight may lead to clinically meaningful reductions in some CVD risk factors, larger weight losses produce greater benefits. The Panel recommends as an initial goal the loss of 5% to 10% of baseline weight within 6 months.  

Step 4: Determining suitable treatment options
If the weight and lifestyle history indicates that the patient has NEVER participated in a comprehensive lifestyle intervention program, it is recommended that he or she be encouraged to undertake such a program prior to adding adjunctive therapies, as a substantial proportion of patients will lose sufficient weight with comprehensive lifestyle treatment alone to improve health.  


If the patient has been unable to lose weight or sustain weight loss with comprehensive lifestyle intervention and they have a BMI ≥30 or ≥27 with comorbidity, adjunctive therapies may be considered.  

Step 5:Diets for Weight Loss  
Prescribe a diet to achieve reduced calorie intake for obese or overweight individuals who would benefit from weight loss, as part of a comprehensive lifestyle intervention. Any 1 of the following methods can be used to reduce food and calorie intake:  



Prescribe 1,200–1,500 kcal/day for women and 1,500–1,800 kcal/day for men

Prescribe a 500 kcal/day or 750 kcal/day energy deficit

Prescribe one of the evidence-based diets that restricts certain food types (such as high-carbohydrate foods, low-fiber foods, or high-fat foods) in order to create an energy deficit by reduced food intake.




Options

A diet from the European Association for the Study of Diabetes Guidelines, which focuses on targeting food groups, rather than formal prescribed energy restriction while still achieving an energy deficit.
Higher protein (25% of total calories from protein, 30% of total calories from fat, 45% of total calories from carbohydrate) with provision of foods that realized energy deficit.
Higher protein Zone™-type diet (5 meals/day, each with 40% of total calories from carbohydrate, 30% of total calories from protein, 30% of total calories from fat) without formal prescribed energy restriction but realized energy deficit.
Lacto-ovo-vegetarian-style diet with prescribed energy restriction.
Low-calorie diet with prescribed energy restriction.


Low-carbohydrate (initially <20 g/day carbohydrate) diet without formal prescribed energy restriction but realized energy deficit.
Low-fat (10% to 25% of total calories from fat) vegan style diet without formal prescribed energy restriction but realized energy deficit.
Low-fat (20% of total calories from fat) diet without formal prescribed energy restriction but realized energy deficit.
Low-glycemic load diet, either with formal prescribed energy restriction or without formal prescribed energy restriction but with realized energy deficit.
Lower fat (≤30% fat), high dairy (4 servings/day) diets with or without increased fiber and/or low-glycemic index/load foods (low-glycemic load) with prescribed energy restriction.
Macronutrient-targeted diets (15% or 25% of total calories from protein; 20% or 40% of total calories from fat; 35%, 45%, 55%, or 65% of total calories from carbohydrate) with prescribed energy restriction



Mediterranean-style diet with prescribed energy restriction.
Moderate protein (12% of total calories from protein, 58% of total calories from carbohydrate, 30% of total calories from fat) with provision of foods that realized energy deficit.
Provision of high-glycemic load or low-glycemic load meals with prescribed energy restriction.
The AHA-style Step 1 diet (with prescribed energy restriction of 1,500–1,800 kcal/day, <30% of total calories from fat, <10% of total calories from saturated fat).

Step 6: Lifestyle interventions and counselling
Advise overweight and obese individuals who would benefit from weight loss to participate for ≥6 months in a comprehensive lifestyle program that assists participants in adhering to a lower calorie diet and in increasing physical activity through the use of behavioral strategies  


Prescribe on site, high-intensity (i.e., ≥14 sessions in 6 months) comprehensive weight loss interventions provided in individual or group sessions by a trained interventionist  

Electronically delivered weight loss programs (including by telephone) that include personalized feedback from a trained interventionist can be prescribed for weight loss but may result in smaller weight loss than face-to-face interventions.  
 


Some commercial-based programs that provide a comprehensive lifestyle intervention can be prescribed as an option for weight loss, provided there is peer-reviewed published evidence of their safety and efficacy  


The principal components of an effective high-intensity, on-site comprehensive lifestyle intervention include:
1) prescription of a moderately-reduced calorie diet;
2) a program of increased physical activity; and
3) the use of behavioral strategies to facilitate adherence to diet and activity recommendations  


Comprehensive lifestyle intervention programs typically prescribe increased aerobic physical activity (such as brisk walking) for >150 minutes/week (equal to >30 minutes/day, most days of the week). Higher levels of physical activity, approximately 200 to 300 minutes/week, are recommended to maintain lost weight or minimize weight regain long-term (>1 year).


Use a very low calorie diet (defined as <800 kcal/day) only in limited circumstances and only when provided by trained practitioners in a medical care setting where medical monitoring and high intensity lifestyle intervention can be provided. Medical supervision is required because of the rapid rate of weight loss and potential for health complications.  


Advise overweight and obese individuals who have lost weight to participate long-term (≥1 year) in a comprehensive weight loss maintenance program.  


For weight loss maintenance, prescribe face-to-face or telephone-delivered weight loss maintenance programs that provide regular contact (monthly or more frequent) with a trained interventionist who helps participants engage in high levels of physical activity (i.e., 200-300 minutes/week), monitor body weight regularly (i.e., weekly or more frequent), and consume a reduced-calorie diet (needed to maintain lower body weight).  

Step 7: Pharmacotherapy
Based on expert opinion, the panelists recommend that for individuals with BMI ≥30 or BMI ≥27 with at least 1 obesity-associated comorbid condition who are motivated to lose weight, pharmacotherapy can be considered as an adjunct to comprehensive lifestyle intervention to help achieve targeted weight loss and health goals.  

Step 8: Selecting Patients for Bariatric Surgical Treatment for Obesity  
Advise adults with a BMI ≥40 or BMI ≥35 with obesity-related comorbid conditions who
are motivated to lose weight and
who have not responded to behavioral treatment with or without pharmacotherapy with sufficient weight loss to achieve targeted health outcome goals that bariatric surgery may be an appropriate option to improve health and offer referral to an experienced bariatric surgeon for consultation and evaluation  


For individuals with a BMI <35, there is insufficient evidence to recommend for or against undergoing bariatric surgical procedures.

Advise patients that choice of a specific bariatric surgical procedure may be affected by patient factors, including age, severity of obesity/BMI, obesity-related comorbid conditions, other operative risk factors, risk of short- and long-term complications, behavioral and psychosocial factors, and patient tolerance for risk as well as provider factors (surgeon and facility).  

Options

Laparoscopic adjustable gastric banding (LAGB)
Laparoscopic Roux-en-Y gastric bypass (RYGB)
Open RYGB
Biliopancreatic diversion (BPD) with and without duodenal switch
Sleeve gastrectomy



Step 9: Assess and treat CVD risk factors and comorbidities
Risk assessment for CVD and diabetes in a person with overweight or class I to III obesity includes history, physical examination, clinical and laboratory assessments, including BP, fasting blood glucose, and fasting lipid panel (expert opinion).
A waist circumference measurement is recommended for individuals with BMI 25 <35kg/m2 to provide additional information on risk.
It is not necessary to measure waist circumference in patients with BMI >35 because the waist circumference will likely be elevated and it will add no additional risk information.
The Panel recommends, by expert opinion, using the current cutpoints (>88 cm or >35 in for women and >102 cm or >40 in for men) as indicative of increased cardiometabolic risk. 

CANDIDATE FOR SURGERY

• Single lesion <5cm (or 6.5cm-UCSF)
• 3 lesions less than 3cm (or less than 4.5 cm)
• Ensure absence of mets/Vascular invasions

CANDIDATE FOR DOWNSTAGING

• Single lesion 5-8cm
• 2-3 lesions <5cm
• 4-5 lesions <3cm
• Total size <8cm

CANDIDATE FOR ABLATION
Single lesion <2cm, not a candidate for surgery

TACE

• Multifocal, no PVT
• Beyond milan

For Liver Transplant
Rule Out Contraindications:

• Mets/PVTT
• Poor performance status
• Infection/organ failure
• Psychosocial issues
  

Dr Abdul Qadeer Khan visited Dr. Saleem Qureshi's Residence To Inquire About His Health. As we all know, he had a fracture of lower end of femur with multiple ligament injuries during his visit to Sweden last month, he was operated there twice, came back to pakistan on last saturday 10th oct, 2015. I want to add some words about the hero of pakistan Dr. Abdul Qadeer Khan, He is also known as Mohsin-e-Pakistan (Urdu: محسن پاکِستان‎, lit. "Benefactor of Pakistan") by some people, more popularly known as A. Q. Khan, is a Pakistani nuclear physicist and a metallurgical engineer, colloquially regarded as the founder of high-enriched uranium (HEU) based Gas-centrifuge uranium enrichment program for Pakistan's integrated atomic bomb project. He founded and established the Kahuta Research Laboratories (KRL) in 1976, being both its senior scientist and the Director-General until his retirement in 2001, and he was an early and vital figure in other science projects. Apart from participating in Pakistan's atomic bomb project, he made major contributions in molecular morphology, physical martensite, and its integrated applications in condensed and material physics.

Right - Dr Abdul Qadeer Khan, Nuclear Scientist
Left - Dr Saleem Qureshi, CEO of ADLD

Left - Dr Abdul Qadeer Khan, Nuclear Scientist
Right - Dr Musarat Iqbal, Co Chairman ADLD

World Diabetes Day Walk at KRL cricket stadium held by the department of medicine KRL Hospital Islamabad. It was headed by Dr Saleem Qureshi, Head of Department of medicine at KRL Hospital and CEO of ADLD (Alliance for diabetes and liver diseases). It was a healthy activity including walk of many kilometers to motivate young people who are at risk of developing diabetes to change their lifestyle and cultivate the habit of active lifestyle. It also included interesting learning activities such as painting the canvas by children who participated in the walk titled inspired to learn.